Combining ONCONASER and Lovastatin to Fight Cancer
Author Information
Author(s): S.M. Mikulski, A. Vieral, Z. Darzynkiewicz, K. Shogen
Primary Institution: Alfacell Corporation
Hypothesis
Can the combination of ONCONASER and lovastatin enhance anti-tumor effects in human cancer cell lines?
Conclusion
The combination of ONCONASER and lovastatin significantly enhances anti-tumor activities in human lung and pancreatic cancer cell lines.
Supporting Evidence
- The combination of ONCONASER and lovastatin showed a significant increase in cell growth inhibition compared to either drug alone.
- Clonogenicity studies confirmed the synergistic interaction between ONCONASER and lovastatin.
- Statistical analysis indicated a significant difference in tumor cell growth inhibition across varying concentrations of ONCONASER.
Takeaway
Researchers found that using two drugs together can help stop cancer cells from growing better than using just one drug alone.
Methodology
The study tested the effects of ONCONASER and lovastatin on three human tumor cell lines using MTT assays and clonogenicity studies.
Limitations
The study was conducted in vitro, and results may not directly translate to in vivo conditions.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website